Pharma & Life Sciences

Anti-Giardial Heterocyclic Compounds for Parasitic Infections

USPTO published patent application US20260098047A1 covering heterocyclic compounds of Formula (I) and (II) for treatment and prevention of Giardiasis (parasitic infection). The application names four inventors and includes pharmaceutical composition claims and methods of using the compounds.

Improved Process for Preparing Risdiplam and Its Intermediates

The USPTO published patent application US20260098048A1 for an improved chemical synthesis process for Risdiplam, a pharmaceutical compound used to treat spinal muscular atrophy. The application also discloses novel intermediates involved in the preparation process. This is a routine patent publication that does not create immediate compliance obligations.

Light-Emitting Heterocyclic Compound for Electronic Devices

USPTO published patent application US20260101670A1 for a heterocyclic compound (Formula 1) for use in light-emitting devices and electronic apparatus. The compound is incorporated into the interlayer and emission layer between electrodes. Inventors: Hwasook Ryu, Hankyu Pak, Dongjun Kim, Chaeyeong Kim, Sanghyun Han. Filing date: March 24, 2025.

Crystalline Form Patent, Tetracyclic Carboxamide, Apr 09

Crystalline Form Patent, Tetracyclic Carboxamide, Apr 09

Rifabutin Analogs for Treatment of M. abscessus Bacterial Infections

USPTO published patent application US20260098046A1 for new rifabutin analog compounds and pharmaceutical compositions for treating bacterial infections, with particular focus on non-tuberculous mycobacteria including M. abscessus. The application was filed on September 29, 2023 by a team of nine inventors. This is a published patent application, not a granted patent.

Lightwave Logic NLO Chromophores 3-Aminocyclohex-2-en-1-one Donor Groups

USPTO published patent application US20260099078A1 by Lightwave Logic, Inc. for nonlinear optical chromophores containing 3-aminocyclohex-2-en-1-one based donor groups. The application covers compositions, materials, and resistive layers comprising these NLO chromophores, methods of making and using them including drying and poling processes, and applications in electro-optic devices such as electro-optic modulators.

KRAS Modulating Compounds

USPTO published patent application US20260098049A1 for KRAS modulating compounds useful as KRAS inhibitors. The application covers compounds, methods of making and using them, and pharmaceutical compositions. Filed August 11, 2025, with 19 inventors listed.

Nonlinear Optical Chromophores with High Steric Hinderance Substituents for Electro-Optic Devices

Lightwave Logic, Inc. published patent application US20260098206A1 covering nonlinear optical (NLO) chromophores with donors having high steric hindrance substituents, compositions/materials comprising such chromophores, and methods of making and using them in electro-optic devices. The application includes methods of drying and poling, and uses in EOMs. Inventors: Ginelle A. Ramann, Barry L. Johnson, Harvey F. Fulo, Will D. Mikkelsen-Yi.

Patent EP3640260A1, Osteogenesis Imperfecta, Genzyme, Baylor

Patent EP3640260A1, Osteogenesis Imperfecta, Genzyme, Baylor

Tunable Luminescent Organic Salts for Enhanced Imaging and Photodynamic Therapy

EPO granted patent EP3664892A2 to Board of Trustees of Michigan State University covering tunable luminescent organic salts for enhanced medical imaging and photodynamic therapy applications. The invention relates to novel compositions and methods for diagnostic imaging and therapeutic treatment using organic salt compounds. The patent designates all EU member states and select European countries as protected territories.